Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a shorter steroid course be just as good for HIV-Related pneumonia?

NCT ID NCT03856229

Disease control Sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a shortened steroid regimen (8 days for moderate, 14 days for severe pneumonia) against the standard 21-day course in 196 HIV patients with Pneumocystis pneumonia. The goal is to see if the shorter treatment is non-inferior in preventing death and complications. Participants must be on standard antibiotics and start steroids within 48 hours of admission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prednisolone (or methylprednisolone equivalent)
What this could lead to
If successful, this could show that a shorter steroid course is just as effective, reducing side effects and simplifying treatment for HIV patients with this type of pneumonia.
What could go wrong
This is a non-inferiority trial, so it may only confirm that the shorter course is not worse, not necessarily better. The results may not apply to patients with other health conditions or those not on standard antibiotics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 196 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2019

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Older than 18 years * To have a gasometry at the admission that confirms moderate or severe PCP. * Patients receiving trimethoprim / sulfamethoxazole in doses of 15 to 20 mg / kg per day from the first 24 hours after admission. * Patients who have begun adjuvant treatment with steroids in the first 48 hours after admission. * No history of chronic pulmonary disease. * APACHE at hospitalization less than 20 points. Exclusion Criteria: * Allergic to TMP/SMX, who have not tolerated desensitization. * History of inflammatory, infectious, autoimmune or neoplastic diseases except Kaposi's sarcoma, which merit the chronic use of steroids. * Pleural or pericardial effusion and meningitis from any cause. * Septic shock not related to PCP. * Subjects who during the hospitalization have been diagnosed with any neoplasia (except Kaposi´s sarcoma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS pneumocystosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV/AIDS Pneumocystis Steroid

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centro de Investigacion en Enfermedades Infecciosas

    México, State of Mexico, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.